|
Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) Clinical research trials and Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD). Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) clinical trial. Subjects often receive the most expert healthcare possible for their Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)  Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)
Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)
For Condition: Attention Deficit and Disruptive Behavior Disorder,Attention Deficit Disorder with Hyperactivity
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to evaluate individuals with Attention Deficit/Hyperactivity Disorder (ADHD) to learn more about the genetics of the disease. This study is part of other ongoing studies of individuals with ADHD. The study participants have already undergone neurobiological measurements, particularly magnetic resonance imaging (MRI) of the brain, through other research studies. As a follow-up to these studies, participants will next undergo psychiatric interviews, neuropsychological tests, and another MRI. In addition to the clinical evaluation of the participants, further research will be conducted on the genetics of ADHD. These genetic studies will evaluate people with ADHD as well as their family members and a control group of healthy people.
Details: 1. This protocol allows the continuing prospective longitudinal study of ADHD probands for whom we have neurobiological measures, particularly quantitative brain MRI. The follow-up consists of structured psychiatric interviews, and neuropsychological tests. Repeat MRI scans are obtained through protocol 89-M-0006. 2. The second purpose of this protocol is a study of the genetics of Attention-Deficit/Hyperactivity Disorder (ADHD) linked to protocol 96-M-0060 (Genetic Aspects of Neurologic and Psychiatric Disorders) and 00-HG-0058 (Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)). Subjects who have ADHD, their family members, and controls are studied under this protocol.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION REQUIREMENTS-PROBANDS: Age of index proband 6-12; age of second (affected) sibling 6-17; age of other affected full siblings (if any) greater than 6 years. DSM-IV diagnosis of ADHD present in all affected siblings, with impairment in at least 2 settings. Age adjusted dimensional ratings (Connor Rating Scales-Revised, and Strengths and Weaknesses of ADHD and Normal Behavior (SWAN)) of hyperactivity/impulsivity or inattention greater than or equal to 95th percentile for index and second sibling. Primary ratings for the index proband will be provided by main teacher. Consent and assent obtained in writing. EXCLUSION CRITERIA: Bilineal transmission of ADHD (ADHD is present in both sides of the family). Presence of other known genetic conditions that are likely to be etiologic. Presence or history of medical conditions that could produce symptoms of ADHD through non-genetic mechanisms (e.g., thyroid disorders, seizure disorders, inborn errors of metabolism, extremely low birth weight (less than 1000 gm), meningitis, intracranial pathology). Presence of other psychiatric disorders that can produce symptoms similar to ADHD (e.g., major depression, bipolar disorder, severe anxiety disorders, pervasive developmental disorders, psychotic disorders, post-traumatic stress disorder). Presence of neuropsychiatric conditions that may confound evaluation of ADHD (e.g., Tourette's syndrome, obsessive-compulsive disorder, or PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcus), intelligence quotient less than 80, reading achievement standard scores less than 75 or reading-intelligence discrepancy greater than 2 SD). INCLUSION REQUIRMENTS-RELATIVES: Subjects must be relatives of probands. Consent and assent obtained in writing. INCLUSION CRITERIA -NORMAL VOLUNTEERS: Same age-range as probands. Parent and teacher ratings within one SD of population means on ADHD/hyperactivity factors. Consent and assent obtained in writing. EXCLUSIONS- NORMAL VOLUNTEERS: Presence of any psychiatric disorders on structured psychiatric interview (DICA-IV). Presence of known genetic conditions. Presence or history of medical conditions.
Total Enrollment: 962
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Wendy Sharp 3014960851
Additional Information:
Study ID Numbers: 850115; 85-M-0115
Study Start Date: June 5, 1985
Record last reviewed: June 30, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001206
Other Attention Deficit And Disruptive Behavior Disorder Studies:
1. Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation
2. Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
3. Assessment of Attentional Functioning in Children with HIV-1 Infection
4. Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
5. Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
Related Studies:
Other Attention Deficit and Disruptive Behavior Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)
|
|
|
|
|
|
|
|
